Modality
Gene Editing
MOA
CGRPant
Target
FGFR
Pathway
Cell Cycle
Melanoma
Development Pipeline
Preclinical
~Feb 2013
→ ~May 2014
Phase 1
~Aug 2014
→ ~Nov 2015
Phase 2
~Feb 2016
→ ~May 2017
Phase 3
Aug 2017
→ Sep 2029
Phase 3Current
NCT07117824
529 pts·Melanoma
2023-04→2026-06·Completed
NCT07170251
215 pts·Melanoma
2017-08→2029-09·Active
744 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-06-052mo awayPh3 Readout· Melanoma
2029-09-283.5y awayPh3 Readout· Melanoma
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P3
Active
P3
Complet…
Catalysts
Ph3 Readout
2026-06-05 · 2mo away
Melanoma
Ph3 Readout
2029-09-28 · 3.5y away
Melanoma
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07117824 | Phase 3 | Melanoma | Completed | 529 | SRI-4 |
| NCT07170251 | Phase 3 | Melanoma | Active | 215 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| INC-2432 | Incyte | Phase 2 | CD47 |